Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   85 Trials   85 Trials   3645 News 


«12...3334353637383940414243...4546»
  • ||||||||||  dexamethasone / Generic mfg., Blincyto (blinatumomab) / Astellas, Amgen
    [VIRTUAL] IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS! (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1877;    
    Overcoming the difficulties to access non-reimbursed orphan drugs requires a team effort, in particular, for therapies with a challenging safety profile where nursing surveillance and care is critical to identify ADR. Our case also suggests that blinatumomab may offer patients with refractory B-ALL a bridge allogeneic transplantation and an opportunity for cure.
  • ||||||||||  dexamethasone / Generic mfg., Blincyto (blinatumomab) / Astellas, Amgen
    [VIRTUAL] IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS! (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1876;    
    Overcoming the difficulties to access non-reimbursed orphan drugs requires a team effort, in particular, for therapies with a challenging safety profile where nursing surveillance and care is critical to identify ADR. Our case also suggests that blinatumomab may offer patients with refractory B-ALL a bridge allogeneic transplantation and an opportunity for cure.
  • ||||||||||  [VIRTUAL] PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1627;    
    Further study is needed to determine what factors can predict which patients with mixed chimerism will remain in remission in order to avoid the morbidity associated with DLI. Notably, the two patients who had distinction of their cells had mixed chimerism of their myeloid compartment, which may have allowed them to maintain suppression of their leukemia with a combination of NK and T lymphocytes.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1567;    
    P1/2
    Therapy with nivolumab, inotuzumab ozogamicin or blinatumomab-based regimens may lead to an objective response in patients with r/r NHL. However, due to the short duration of the response, consolidation with allo-HSCT is needed.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. (Pubmed Central) -  Feb 6, 2020   
    CAR T therapy uses genetically modified autologous T cells directed against CD19, a known target on B cells. CRS and neurological symptoms, formally termed as immune-effector-cell-associated neurological syndrome, have been described along with hypogammaglobulinemia, cytopenias, and infections.
  • ||||||||||  Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults. (Pubmed Central) -  Feb 6, 2020   
    Eighty percent of inotuzumab-treated B-ALL patients may achieve a CR state. This review is focused on the biological and clinical activities of CD22 antibodies in B-ALL, and provides evidence about the potential role played by qualitative and quantitative analysis of the CD22 molecule on individual B-ALL blasts in predicting the depletion of leukemic cells, and, ultimately, leading to better clinical response rates.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Pathologic Findings in Patients with Refractory B-Lymphoblastic Leukemia Treated with Blinatumomab (LACC 403 A) -  Jan 24, 2020 - Abstract #USCAP2020USCAP_702;    
    Patients treated with blinatumomab and with refractory B-lymphoblastic leukemia show a propensity for recurrence in unusual extramedullary sites. Interestingly, these extramedullary recurrences occur in the setting of negative bone marrow biopsies, exhibit retention of surface expression of CD19, and do not show an association with specific cytogenetic abnormalities.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Oncaspar liquid (pegaspargase) / Takeda
    Updates in Acute Lymphoblastic Leukemia: Pediatric, Young Adult, Adult (Ballroom BC) -  Jan 14, 2020 - Abstract #HOPA2020HOPA_81;    
    It is important that pharmacists are familiar with indications for appropriate use, dosing strategies, monitoring, and toxicity management of available asparagine depleting enzymes. Learning Objectives: Recognize definition of pediatric, young adult, and adult patients with ALL and corresponding risk factors Identify toxicities of pegaspargase therapy and propose monitoring plans based on patient characteristics Analyze the data supporting the use of blinatumomab and inotuzumab for relapsed/refractory disease and minimal residual disease positive ALL Recommend maintenance tyrosine kinase inhibitor therapy in patients after HSCT based on patient and disease characteristics
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Blinatumomab in Ph-like Acute Lymphoblastic Leukemia – an Institutional Experience (World Center Marriott - Palms & Cypress Foyers) -  Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_967;    
    Ph-like ALL patients are more likely to remain MRD-positive after induction therapy (Jain et al, Blood 2017); utilizing blinatumomab as frontline or for MRD in first CR may improve outcomes. Further investigation with larger sample size and multi-center experience is required to fully determine the efficacy and role of blinatumomab, other immunotherapies, and allo-HSCT in the treatment of Ph-like ALL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial primary completion date:  Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jan 7, 2020   
    P1,  N=44, Suspended, 
    Further investigation with larger sample size and multi-center experience is required to fully determine the efficacy and role of blinatumomab, other immunotherapies, and allo-HSCT in the treatment of Ph-like ALL. Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Taking a "BiTE out of ALL" - Blinatumomab approval for MRD positive ALL. (Pubmed Central) -  Dec 25, 2019   
    MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Study of aromatic profile of different crosses of Monastrell white wines. (Pubmed Central) -  Dec 19, 2019   
    The present study reports the first investigation of the volatile composition and sensory characteristics of directed crosses white wines obtained from Monastrell and other varieties, such as Cabernet Sauvignon, Syrah, Tempranillo and Verdejo. The results obtained indicate that the use of some of these white crosses could be a good option for growing them in this Mediterranean area as a result of the contribution of a good quality in the wine aroma.